95 related articles for article (PubMed ID: 17203891)
1. Prognostic significance of clusterin immunoreactivity in breast cancer.
Krüger S; Ola V; Fischer D; Feller AC; Friedrich M
Neoplasma; 2007; 54(1):46-50. PubMed ID: 17203891
[TBL] [Abstract][Full Text] [Related]
2. Clusterin overexpression and relapse-free survival in breast cancer.
Yom CK; Woo HY; Min SY; Kang SY; Kim HS
Anticancer Res; 2009 Oct; 29(10):3909-12. PubMed ID: 19846927
[TBL] [Abstract][Full Text] [Related]
3. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer.
Rhee J; Han SW; Oh DY; Kim JH; Im SA; Han W; Park IA; Noh DY; Bang YJ; Kim TY
BMC Cancer; 2008 Oct; 8():307. PubMed ID: 18947390
[TBL] [Abstract][Full Text] [Related]
4. Value of clusterin immunoreactivity as a predictive factor in muscle-invasive urothelial bladder carcinoma.
Krüger S; Mahnken A; Kausch I; Feller AC
Urology; 2006 Jan; 67(1):105-9. PubMed ID: 16413343
[TBL] [Abstract][Full Text] [Related]
5. Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?
Maehle BO; Collett K; Tretli S; Akslen LA; Grotmol T
APMIS; 2009 Sep; 117(9):644-50. PubMed ID: 19703124
[TBL] [Abstract][Full Text] [Related]
6. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
7. High MMP-1 mRNA expression is a risk factor for disease-free and overall survivals in patients with invasive breast carcinoma.
Cheng S; Tada M; Hida Y; Asano T; Kuramae T; Takemoto N; Hamada J; Miyamoto M; Hirano S; Kondo S; Moriuchi T
J Surg Res; 2008 May; 146(1):104-9. PubMed ID: 17663001
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer.
Borgquist S; Jögi A; Pontén F; Rydén L; Brennan DJ; Jirström K
Breast Cancer Res; 2008; 10(5):R79. PubMed ID: 18808688
[TBL] [Abstract][Full Text] [Related]
9. Ki-67 expression gives additional prognostic information on St. Gallen 2007 and Adjuvant! Online risk categories in early breast cancer.
Jung SY; Han W; Lee JW; Ko E; Kim E; Yu JH; Moon HG; Park IA; Oh DY; Im SA; Kim TY; Hwang KT; Kim SW; Noh DY
Ann Surg Oncol; 2009 May; 16(5):1112-21. PubMed ID: 19219507
[TBL] [Abstract][Full Text] [Related]
10. Expression of cyclins E, A, and B, and prognosis in lymph node-negative breast cancer.
Kühling H; Alm P; Olsson H; Fernö M; Baldetorp B; Parwaresch R; Rudolph P
J Pathol; 2003 Apr; 199(4):424-31. PubMed ID: 12635132
[TBL] [Abstract][Full Text] [Related]
11. Prognostic relevance of proliferative activity evaluated by Mib-1 immunostaining in node negative breast cancer.
Neri A; Marrelli D; Pedrazzani C; Caruso S; De Stefano A; Mariani F; Megha T; De Marco G; Corso G; Pinto E; Roviello F
Eur J Surg Oncol; 2008 Dec; 34(12):1299-303. PubMed ID: 18164172
[TBL] [Abstract][Full Text] [Related]
12. A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma.
Di Saverio S; Gutierrez J; Avisar E
Breast Cancer Res Treat; 2008 Oct; 111(3):541-7. PubMed ID: 18026874
[TBL] [Abstract][Full Text] [Related]
13. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
14. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
16. Bcl-2 expression predicts local relapse for early-stage breast cancer receiving conserving surgery and radiotherapy.
Yang Q; Moran MS; Haffty BG
Breast Cancer Res Treat; 2009 May; 115(2):343-8. PubMed ID: 18516673
[TBL] [Abstract][Full Text] [Related]
17. Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma.
Makretsov NA; Huntsman DG; Nielsen TO; Yorida E; Peacock M; Cheang MC; Dunn SE; Hayes M; van de Rijn M; Bajdik C; Gilks CB
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6143-51. PubMed ID: 15448001
[TBL] [Abstract][Full Text] [Related]
18. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
19. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma.
van der Vegt B; de Roos MA; Peterse JL; Patriarca C; Hilkens J; de Bock GH; Wesseling J
Histopathology; 2007 Sep; 51(3):322-35. PubMed ID: 17645748
[TBL] [Abstract][Full Text] [Related]
20. Survivin expression predicts early recurrence in early-stage breast cancer.
Yamashita S; Masuda Y; Kurizaki T; Haga Y; Murayama T; Ikei S; Kamei M; Takeno S; Kawahara K
Anticancer Res; 2007; 27(4C):2803-8. PubMed ID: 17695451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
